C
Craig H. Smith
Researcher at Genentech
Publications - 37
Citations - 6741
Craig H. Smith is an academic researcher from Genentech. The author has contributed to research in topics: Optic neuritis & Multiple sclerosis. The author has an hindex of 19, co-authored 37 publications receiving 6128 citations. Previous affiliations of Craig H. Smith include University of Pennsylvania & University of Washington.
Papers
More filters
Journal ArticleDOI
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser,Emmanuelle Waubant,Douglas L. Arnold,Timothy Vollmer,Jack P. Antel,Robert J. Fox,Amit Bar-Or,Michael Panzara,Neena Sarkar,Sunil Agarwal,Annette Langer-Gould,Craig H. Smith +11 more
TL;DR: A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
Journal ArticleDOI
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Roy W. Beck,Patricia A. Cleary,Malcolm M. Anderson,John L. Keltner,William T. Shults,David I. Kaufman,Edward G. Buckley,James J. Corbett,Mark J. Kupersmith,Neil R. Miller,Peter J. Savino,John Guy,Jonathan D. Trobe,John A. McCrary,Craig H. Smith,Georgia A. Chrousos,H. Stanley Thompson,Barrett Katz,Michael C. Brodsky,James Goodwin,Constance W. Atwell +20 more
TL;DR: Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields, contrast sensitivity, and color vision but not better visual acuity.
Journal ArticleDOI
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker,Paul O'Connor,Mark S. Freedman,Peter A. Calabresi,Jack P. Antel,Jack H. Simon,Stephen L. Hauser,Emmanuelle Waubant,Timothy Vollmer,Hillel Panitch,Jiameng Zhang,Peter Chin,Craig H. Smith +12 more
TL;DR: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS).
Journal ArticleDOI
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or,Peter A. Calabresi,Douglas L. Arnold,Clyde E. Markowitz,Stuart Shafer,Lloyd H. Kasper,Emmanuelle Waubant,Suzanne Gazda,Robert J. Fox,Michael Panzara,Neena Sarkar,Sunil Agarwal,Craig H. Smith +12 more
TL;DR: An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy, and events were limited to mild‐to‐moderate infusion‐associated events, which tended to decrease with subsequent infusions.
Journal ArticleDOI
Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up
Michael C. Brodsky,Michael C. Brodsky,Sarkis Nazarian,Silvia Orengo-Nania,George J. Hutton,Edward G. Buckley,E. Wayne Massey,M. Tariq Bhatti,M. Tariq Bhatti,Melvin Greer,James Goodwin,Michael Wall,Peter J. Savino,Thomas Leist,Neil R. Miller,David N. Irani,Jonathan D. Trobe,Wayne T. Cornblath,David I. Kaufman,Eric R. Eggenberger,Mark J. Kupersmith,William T. Shults,Leslie McAllister,Steve Hamilton,Roy W. Beck,Mariya Dontchev,Robin L. Gal,Craig Kollman,John L. Keltner,Craig H. Smith +29 more
TL;DR: The presence of brain MRI abnormalities at the time of an optic neuritis attack is a strong predictor of the 15-year risk of MS.